Laura Mendez

HOUSTON, April 13, 2026 /PRNewswire/ — Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Each will highlight the company’s approach to targeting the Wnt/β-catenin pathway, one of the most frequently dysregulated signaling programs in cancer.

Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient has been …

Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed Read More »

Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma HOUSTON, Feb. 10, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today announced that the first patient has …

Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma Read More »

Iterion is excited to present new data on Tegavivint at the upcoming AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–25 in Boston. Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC). Tegavivint, …

Iterion to present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More »

HOUSTON, Feb. 20, 2024 /PRNewswire/ — Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma (HCC) that have failed at least …

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments Read More »

Iterion announces collaboration with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute.

Iterion shares results from collaboration with Cancer Research UK (CRUK)

Results announced from dose escalation study of tegavivint in desmoid tumors.